Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
viloxazine
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N06AX29
|
| gptkbp:brand |
viloxazine hydrochloride
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Verzen
|
| gptkbp:indication |
gptkb:attention_deficit_hyperactivity_disorder
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Supernus_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
norepinephrine reuptake inhibition
serotonin modulation |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting fatigue irritability somnolence decreased appetite |
| gptkbp:usedFor |
treatment of ADHD
|
| gptkbp:bfsParent |
gptkb:Hendrik_Marsman
|
| gptkbp:bfsLayer |
7
|